TY - JOUR
T1 - Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
AU - Gittler, Julia K.
AU - Shemer, Avner
AU - Suárez-Fariñas, Mayte
AU - Fuentes-Duculan, Judilyn
AU - Gulewicz, Kara J.
AU - Wang, Claire Q.F.
AU - Mitsui, Hiroshi
AU - Cardinale, Irma
AU - De Guzman Strong, Cristina
AU - Krueger, James G.
AU - Guttman-Yassky, Emma
N1 - Funding Information:
Disclosure of potential conflict of interest: J. G. Krueger has consultant arrangements with Centercore, Eli Lilly, and Pfizer and has received grants from Amgen, Centercore, Eli Lilly, Merck, and Pfizer . E. Guttman-Yassky has received grants from the Dermatology Foundation to Mount Sinai School of Medicine and has consultant arrangements with Regeneron, Merck, Pfizer, and Stiefel. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
J.G.K. and M.S.-F. were supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR) , a component of the National Institutes of Health (NIH) and the NIH Roadmap for Medical Research. C.D.S. was supported by the NIH (R00AR055948) . E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award .
PY - 2012/12
Y1 - 2012/12
N2 - Background: Atopic dermatitis (AD) is a common disease with an increasing prevalence. The primary pathogenesis of the disease is still elusive, resulting in the lack of specific treatments. AD is currently considered a biphasic disease, with TH2 predominating in acute disease and a switch to TH1 characterizing chronic disease. Elucidation of the molecular factors that participate in the onset of new lesions and maintenance of chronic disease is critical for the development of targeted therapeutics. Objectives: We sought to characterize the mechanisms underlying the onset and maintenance of AD. Methods: We investigated intrapersonal sets of transcriptomes from nonlesional skin and acute and chronic lesions of 10 patients with AD through genomic, molecular, and cellular profiling. Results: Our study associated the onset of acute lesions with a striking increase in a subset of terminal differentiation proteins, specifically the cytokine-modulated S100A7, S100A8, and S100A9. Acute disease was also associated with significant increases in gene expression levels of major TH22 and TH2 cytokines and smaller increases in IL-17 levels. A lesser induction of TH1- associated genes was detected in acute disease, although some were significantly upregulated in chronic disease. Further significant intensification of major TH22 and TH2 cytokines was observed between acute and chronic lesions. Conclusions: Our data identified increased S100A7, S100A8, and S100A9 gene expression with AD initiation and concomitant activation of T H2 and TH22 cytokines. Our findings support a model of progressive activation of TH2 and TH22 immune axes from the acute to chronic phases, expanding the prevailing view of pathogenesis with important therapeutic implications.
AB - Background: Atopic dermatitis (AD) is a common disease with an increasing prevalence. The primary pathogenesis of the disease is still elusive, resulting in the lack of specific treatments. AD is currently considered a biphasic disease, with TH2 predominating in acute disease and a switch to TH1 characterizing chronic disease. Elucidation of the molecular factors that participate in the onset of new lesions and maintenance of chronic disease is critical for the development of targeted therapeutics. Objectives: We sought to characterize the mechanisms underlying the onset and maintenance of AD. Methods: We investigated intrapersonal sets of transcriptomes from nonlesional skin and acute and chronic lesions of 10 patients with AD through genomic, molecular, and cellular profiling. Results: Our study associated the onset of acute lesions with a striking increase in a subset of terminal differentiation proteins, specifically the cytokine-modulated S100A7, S100A8, and S100A9. Acute disease was also associated with significant increases in gene expression levels of major TH22 and TH2 cytokines and smaller increases in IL-17 levels. A lesser induction of TH1- associated genes was detected in acute disease, although some were significantly upregulated in chronic disease. Further significant intensification of major TH22 and TH2 cytokines was observed between acute and chronic lesions. Conclusions: Our data identified increased S100A7, S100A8, and S100A9 gene expression with AD initiation and concomitant activation of T H2 and TH22 cytokines. Our findings support a model of progressive activation of TH2 and TH22 immune axes from the acute to chronic phases, expanding the prevailing view of pathogenesis with important therapeutic implications.
KW - Atopic dermatitis
KW - IL-22
KW - S100A7
KW - S100A8
KW - S100A9
KW - T 17
KW - T2
KW - T22
KW - acute
KW - chronic
KW - terminal differentiation
UR - http://www.scopus.com/inward/record.url?scp=84870294267&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2012.07.012
DO - 10.1016/j.jaci.2012.07.012
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 22951056
AN - SCOPUS:84870294267
SN - 0091-6749
VL - 130
SP - 1344
EP - 1354
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -